Drug Profile
YM 57158
Alternative Names: YM 158Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Antiasthmatics
- Mechanism of Action Leukotriene D4 receptor antagonists; Thromboxane A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic-rhinitis in Europe (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in Europe (PO)
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma